Log in to your Inderes Free account to see all free content on this page.

Photocure

Less than 1K followers

PHO

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Photocure is a medical technology company. The company specializes in photodynamic technology solutions. The solutions are used to treat diseases that cause bladder cancer and HPV. The main markets are dermatology and oncology, where the products are used by hospitals and research institutes worldwide. The company was founded in 1993 and is headquartered in Oslo, Norway.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

4.5.

2026

General meeting '26

7.5.

2026

Interim report Q1'26

29.7.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release13 hours ago

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Press release13 hours ago

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Regulatory press release3/3/2026, 9:35 AM

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release3/3/2026, 9:34 AM

Photocure: Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Press release2/27/2026, 9:17 AM

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe

Regulatory press release2/18/2026, 6:00 AM

Photocure ASA: Results for the fourth quarter of 2025

Regulatory press release2/18/2026, 6:00 AM

Photocure ASA: Results for the fourth quarter of 2025

Regulatory press release2/11/2026, 4:06 PM

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Regulatory press release2/11/2026, 4:06 PM

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Regulatory press release1/12/2026, 4:42 PM

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Press release1/12/2026, 4:00 PM

Photocure: New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Regulatory press release12/29/2025, 1:22 PM

PHO: Financial calendar

Regulatory press release12/8/2025, 7:00 AM

The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Press release12/8/2025, 7:00 AM

Photocure: The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Regulatory press release11/19/2025, 7:00 AM

PHO: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Press release11/19/2025, 7:00 AM

Photocure: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Regulatory press release10/31/2025, 7:24 AM

Photocure ASA: Notification of primary insider transaction

Regulatory press release10/31/2025, 7:24 AM

Photocure ASA: Notification of primary insider transaction

Regulatory press release10/29/2025, 6:00 AM

Photocure ASA: Results for the third quarter of 2025

Regulatory press release10/29/2025, 6:00 AM

Photocure ASA: Results for the third quarter of 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.